HLA Typing for Transplant Market By Technology (Molecular Assay, Non-Molecular Assay) , By Product (Instruments, Reagents & Consumables, Software & Services) By Application (Diagnostic, Research) By Type (Organ Transplant, Tissue) By End User (Independent Reference Laboratories, Hospital & Transplant Center, Other) : Global Opportunity Analysis and Industry Forecast, 2024-2033
HLA Typing for Transplant Market
The HLA typing for transplant market was valued at $0.9 billion in 2023 and is projected to reach $1.7 billion by 2033, growing at a CAGR of 6.6% from 2024 to 2033.
Human leukocyte antigen (HLA) typing for transplant is an analysis procedure that determines the compatibility between donor and recipient for organ transplant. The proteins transcribed by HLA genes play a critical role in the immune system of humans. The most common forms of organ transplants that involve HLA typing are stem cell and solid organ transplants. A high percentage of HLA matches is critical to ensure that donor or recipient cells do not attack the other post-transplantation.
Rise in the prevalence of chronic conditions such as liver cirrhosis and kidney diseases has fueled organ transplant procedures globally, driving the HLA typing for transplant market. In addition, the availability of effective reimbursement policies for HLA typing and organ transplantation has enhanced their accessibility for patients, augmenting the development of the market. An emerging trend poised to dominate the HLA typing for transplant market is the deployment of third-generation sequencing techniques such as single-molecule real-time sequencing and Oxford Nanopore. These techniques improve accuracy, reduce ambiguity, and enhance the assessment of compatibility for transplantation.
However, the high expenditure associated with HLA typing and organ transplantations deters several patients from opting for such treatments, restraining the development of the market. Moreover, the scarcity of available organs reduces the opportunities for transplantations, which impacts the overall demand for HLA typing and hampers the market growth. On the contrary, rise in awareness regarding the necessity of organ donation has upsurged the number of individuals signing up for it post their demise. For instance, a novel annual record was set in the U.S. in 2023 owing to the availability of more than 16,000 deceased organ donors. Therefore, rise in the number of readily available organs for transplant is projected to boost HLA typing for testing the compatibility, opening new avenues for the market.
Segment Review
The HLA typing for transplant market is segmented into technology, product, application, type, end user, and region. On the basis of technology, the market is bifurcated into molecular assay and non-molecular assay. Depending on product, it is divided into instruments, reagents & consumables, and software & services. According to application, it is bifurcated into diagnostic and research. As per type, it is classified into organ transplant and tissue. By end user, it is categorized into independent reference laboratories, hospital & transplant center, and other. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of technology, the molecular assay segment held a high share of the market in 2023.
Depending on product, the reagents & consumables segment acquired a high stake in the market in 2023.
According to application, the diagnostic segment dominated the market in 2023.
As per type, the organ transplant segment was the highest shareholder in 2023.
By end user, the independent reference laboratories segment accounted for a high share of the market in 2023.
Region wise, North America was the highest revenue generator in 2023.
Competition Analysis
The leading players operating in the global HLA typing for transplant market include Luminex Corporation, Pacific Biosciences of California, Inc., Abbott Laboratories, Bio-Rad Laboratories, BioReference Laboratories, Qiagen N.V, F. Hoffmann-La Roche Ltd., Illumina Inc., Fujirebio, and BAG Diagnostic GmbH. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.
Key Market Segments
By Technology
Molecular Assay
Non-Molecular Assay
By Product
Instruments
Reagents Consumables
Software Services
By Application
Diagnostic
Research
By Type
Organ Transplant
Tissue
By End User
Independent Reference Laboratories
Hospital Transplant Center
Other
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Luminex Corporation
Pacific Biosciences of California, Inc
Abbott Laboratories
Bio-Rad Laboratories
BioReference Laboratories
Qiagen N.V
F. Hoffmann-La Roche Ltd.
Illumina Inc.
Fujirebio
BAG Diagnostic GmbH
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Technology
- 4.2. Molecular Assay
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Non-Molecular Assay
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- CHAPTER 5: HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Product
- 5.2. Instruments
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Reagents Consumables
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Software Services
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
- CHAPTER 6: HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Application
- 6.2. Diagnostic
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Research
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- CHAPTER 7: HLA TYPING FOR TRANSPLANT MARKET, BY TYPE
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Type
- 7.2. Organ Transplant
- 7.2.1. Key Market Trends, Growth Factors and Opportunities
- 7.2.2. Market Size and Forecast, By Region
- 7.2.3. Market Share Analysis, By Country
- 7.3. Tissue
- 7.3.1. Key Market Trends, Growth Factors and Opportunities
- 7.3.2. Market Size and Forecast, By Region
- 7.3.3. Market Share Analysis, By Country
- CHAPTER 8: HLA TYPING FOR TRANSPLANT MARKET, BY END USER
- 8.1. Market Overview
- 8.1.1 Market Size and Forecast, By End User
- 8.2. Independent Reference Laboratories
- 8.2.1. Key Market Trends, Growth Factors and Opportunities
- 8.2.2. Market Size and Forecast, By Region
- 8.2.3. Market Share Analysis, By Country
- 8.3. Hospital Transplant Center
- 8.3.1. Key Market Trends, Growth Factors and Opportunities
- 8.3.2. Market Size and Forecast, By Region
- 8.3.3. Market Share Analysis, By Country
- 8.4. Other
- 8.4.1. Key Market Trends, Growth Factors and Opportunities
- 8.4.2. Market Size and Forecast, By Region
- 8.4.3. Market Share Analysis, By Country
- CHAPTER 9: HLA TYPING FOR TRANSPLANT MARKET, BY REGION
- 9.1. Market Overview
- 9.1.1 Market Size and Forecast, By Region
- 9.2. North America
- 9.2.1. Key Market Trends and Opportunities
- 9.2.2. Market Size and Forecast, By Technology
- 9.2.3. Market Size and Forecast, By Product
- 9.2.4. Market Size and Forecast, By Application
- 9.2.5. Market Size and Forecast, By Type
- 9.2.6. Market Size and Forecast, By End User
- 9.2.7. Market Size and Forecast, By Country
- 9.2.8. U.S. HLA Typing for Transplant Market
- 9.2.8.1. Market Size and Forecast, By Technology
- 9.2.8.2. Market Size and Forecast, By Product
- 9.2.8.3. Market Size and Forecast, By Application
- 9.2.8.4. Market Size and Forecast, By Type
- 9.2.8.5. Market Size and Forecast, By End User
- 9.2.9. Canada HLA Typing for Transplant Market
- 9.2.9.1. Market Size and Forecast, By Technology
- 9.2.9.2. Market Size and Forecast, By Product
- 9.2.9.3. Market Size and Forecast, By Application
- 9.2.9.4. Market Size and Forecast, By Type
- 9.2.9.5. Market Size and Forecast, By End User
- 9.2.10. Mexico HLA Typing for Transplant Market
- 9.2.10.1. Market Size and Forecast, By Technology
- 9.2.10.2. Market Size and Forecast, By Product
- 9.2.10.3. Market Size and Forecast, By Application
- 9.2.10.4. Market Size and Forecast, By Type
- 9.2.10.5. Market Size and Forecast, By End User
- 9.3. Europe
- 9.3.1. Key Market Trends and Opportunities
- 9.3.2. Market Size and Forecast, By Technology
- 9.3.3. Market Size and Forecast, By Product
- 9.3.4. Market Size and Forecast, By Application
- 9.3.5. Market Size and Forecast, By Type
- 9.3.6. Market Size and Forecast, By End User
- 9.3.7. Market Size and Forecast, By Country
- 9.3.8. Germany HLA Typing for Transplant Market
- 9.3.8.1. Market Size and Forecast, By Technology
- 9.3.8.2. Market Size and Forecast, By Product
- 9.3.8.3. Market Size and Forecast, By Application
- 9.3.8.4. Market Size and Forecast, By Type
- 9.3.8.5. Market Size and Forecast, By End User
- 9.3.9. France HLA Typing for Transplant Market
- 9.3.9.1. Market Size and Forecast, By Technology
- 9.3.9.2. Market Size and Forecast, By Product
- 9.3.9.3. Market Size and Forecast, By Application
- 9.3.9.4. Market Size and Forecast, By Type
- 9.3.9.5. Market Size and Forecast, By End User
- 9.3.10. UK HLA Typing for Transplant Market
- 9.3.10.1. Market Size and Forecast, By Technology
- 9.3.10.2. Market Size and Forecast, By Product
- 9.3.10.3. Market Size and Forecast, By Application
- 9.3.10.4. Market Size and Forecast, By Type
- 9.3.10.5. Market Size and Forecast, By End User
- 9.3.11. Italy HLA Typing for Transplant Market
- 9.3.11.1. Market Size and Forecast, By Technology
- 9.3.11.2. Market Size and Forecast, By Product
- 9.3.11.3. Market Size and Forecast, By Application
- 9.3.11.4. Market Size and Forecast, By Type
- 9.3.11.5. Market Size and Forecast, By End User
- 9.3.12. Spain HLA Typing for Transplant Market
- 9.3.12.1. Market Size and Forecast, By Technology
- 9.3.12.2. Market Size and Forecast, By Product
- 9.3.12.3. Market Size and Forecast, By Application
- 9.3.12.4. Market Size and Forecast, By Type
- 9.3.12.5. Market Size and Forecast, By End User
- 9.3.13. Rest Of Europe HLA Typing for Transplant Market
- 9.3.13.1. Market Size and Forecast, By Technology
- 9.3.13.2. Market Size and Forecast, By Product
- 9.3.13.3. Market Size and Forecast, By Application
- 9.3.13.4. Market Size and Forecast, By Type
- 9.3.13.5. Market Size and Forecast, By End User
- 9.4. Asia-Pacific
- 9.4.1. Key Market Trends and Opportunities
- 9.4.2. Market Size and Forecast, By Technology
- 9.4.3. Market Size and Forecast, By Product
- 9.4.4. Market Size and Forecast, By Application
- 9.4.5. Market Size and Forecast, By Type
- 9.4.6. Market Size and Forecast, By End User
- 9.4.7. Market Size and Forecast, By Country
- 9.4.8. Japan HLA Typing for Transplant Market
- 9.4.8.1. Market Size and Forecast, By Technology
- 9.4.8.2. Market Size and Forecast, By Product
- 9.4.8.3. Market Size and Forecast, By Application
- 9.4.8.4. Market Size and Forecast, By Type
- 9.4.8.5. Market Size and Forecast, By End User
- 9.4.9. China HLA Typing for Transplant Market
- 9.4.9.1. Market Size and Forecast, By Technology
- 9.4.9.2. Market Size and Forecast, By Product
- 9.4.9.3. Market Size and Forecast, By Application
- 9.4.9.4. Market Size and Forecast, By Type
- 9.4.9.5. Market Size and Forecast, By End User
- 9.4.10. Australia HLA Typing for Transplant Market
- 9.4.10.1. Market Size and Forecast, By Technology
- 9.4.10.2. Market Size and Forecast, By Product
- 9.4.10.3. Market Size and Forecast, By Application
- 9.4.10.4. Market Size and Forecast, By Type
- 9.4.10.5. Market Size and Forecast, By End User
- 9.4.11. India HLA Typing for Transplant Market
- 9.4.11.1. Market Size and Forecast, By Technology
- 9.4.11.2. Market Size and Forecast, By Product
- 9.4.11.3. Market Size and Forecast, By Application
- 9.4.11.4. Market Size and Forecast, By Type
- 9.4.11.5. Market Size and Forecast, By End User
- 9.4.12. South Korea HLA Typing for Transplant Market
- 9.4.12.1. Market Size and Forecast, By Technology
- 9.4.12.2. Market Size and Forecast, By Product
- 9.4.12.3. Market Size and Forecast, By Application
- 9.4.12.4. Market Size and Forecast, By Type
- 9.4.12.5. Market Size and Forecast, By End User
- 9.4.13. Rest of Asia-Pacific HLA Typing for Transplant Market
- 9.4.13.1. Market Size and Forecast, By Technology
- 9.4.13.2. Market Size and Forecast, By Product
- 9.4.13.3. Market Size and Forecast, By Application
- 9.4.13.4. Market Size and Forecast, By Type
- 9.4.13.5. Market Size and Forecast, By End User
- 9.5. LAMEA
- 9.5.1. Key Market Trends and Opportunities
- 9.5.2. Market Size and Forecast, By Technology
- 9.5.3. Market Size and Forecast, By Product
- 9.5.4. Market Size and Forecast, By Application
- 9.5.5. Market Size and Forecast, By Type
- 9.5.6. Market Size and Forecast, By End User
- 9.5.7. Market Size and Forecast, By Country
- 9.5.8. Brazil HLA Typing for Transplant Market
- 9.5.8.1. Market Size and Forecast, By Technology
- 9.5.8.2. Market Size and Forecast, By Product
- 9.5.8.3. Market Size and Forecast, By Application
- 9.5.8.4. Market Size and Forecast, By Type
- 9.5.8.5. Market Size and Forecast, By End User
- 9.5.9. Saudi Arabia HLA Typing for Transplant Market
- 9.5.9.1. Market Size and Forecast, By Technology
- 9.5.9.2. Market Size and Forecast, By Product
- 9.5.9.3. Market Size and Forecast, By Application
- 9.5.9.4. Market Size and Forecast, By Type
- 9.5.9.5. Market Size and Forecast, By End User
- 9.5.10. South Africa HLA Typing for Transplant Market
- 9.5.10.1. Market Size and Forecast, By Technology
- 9.5.10.2. Market Size and Forecast, By Product
- 9.5.10.3. Market Size and Forecast, By Application
- 9.5.10.4. Market Size and Forecast, By Type
- 9.5.10.5. Market Size and Forecast, By End User
- 9.5.11. Rest of LAMEA HLA Typing for Transplant Market
- 9.5.11.1. Market Size and Forecast, By Technology
- 9.5.11.2. Market Size and Forecast, By Product
- 9.5.11.3. Market Size and Forecast, By Application
- 9.5.11.4. Market Size and Forecast, By Type
- 9.5.11.5. Market Size and Forecast, By End User
- CHAPTER 10: COMPETITIVE LANDSCAPE
- 10.1. Introduction
- 10.2. Top Winning Strategies
- 10.3. Product Mapping Of Top 10 Player
- 10.4. Competitive Dashboard
- 10.5. Competitive Heatmap
- 10.6. Top Player Positioning, 2023
- CHAPTER 11: COMPANY PROFILES
- 11.1. Luminex Corporation
- 11.1.1. Company Overview
- 11.1.2. Key Executives
- 11.1.3. Company Snapshot
- 11.1.4. Operating Business Segments
- 11.1.5. Product Portfolio
- 11.1.6. Business Performance
- 11.1.7. Key Strategic Moves and Developments
- 11.2. Pacific Biosciences Of California, Inc
- 11.2.1. Company Overview
- 11.2.2. Key Executives
- 11.2.3. Company Snapshot
- 11.2.4. Operating Business Segments
- 11.2.5. Product Portfolio
- 11.2.6. Business Performance
- 11.2.7. Key Strategic Moves and Developments
- 11.3. Abbott Laboratories
- 11.3.1. Company Overview
- 11.3.2. Key Executives
- 11.3.3. Company Snapshot
- 11.3.4. Operating Business Segments
- 11.3.5. Product Portfolio
- 11.3.6. Business Performance
- 11.3.7. Key Strategic Moves and Developments
- 11.4. Bio-Rad Laboratories
- 11.4.1. Company Overview
- 11.4.2. Key Executives
- 11.4.3. Company Snapshot
- 11.4.4. Operating Business Segments
- 11.4.5. Product Portfolio
- 11.4.6. Business Performance
- 11.4.7. Key Strategic Moves and Developments
- 11.5. BioReference Laboratories
- 11.5.1. Company Overview
- 11.5.2. Key Executives
- 11.5.3. Company Snapshot
- 11.5.4. Operating Business Segments
- 11.5.5. Product Portfolio
- 11.5.6. Business Performance
- 11.5.7. Key Strategic Moves and Developments
- 11.6. Qiagen N.V
- 11.6.1. Company Overview
- 11.6.2. Key Executives
- 11.6.3. Company Snapshot
- 11.6.4. Operating Business Segments
- 11.6.5. Product Portfolio
- 11.6.6. Business Performance
- 11.6.7. Key Strategic Moves and Developments
- 11.7. F. Hoffmann-La Roche Ltd.
- 11.7.1. Company Overview
- 11.7.2. Key Executives
- 11.7.3. Company Snapshot
- 11.7.4. Operating Business Segments
- 11.7.5. Product Portfolio
- 11.7.6. Business Performance
- 11.7.7. Key Strategic Moves and Developments
- 11.8. Illumina Inc.
- 11.8.1. Company Overview
- 11.8.2. Key Executives
- 11.8.3. Company Snapshot
- 11.8.4. Operating Business Segments
- 11.8.5. Product Portfolio
- 11.8.6. Business Performance
- 11.8.7. Key Strategic Moves and Developments
- 11.9. Fujirebio
- 11.9.1. Company Overview
- 11.9.2. Key Executives
- 11.9.3. Company Snapshot
- 11.9.4. Operating Business Segments
- 11.9.5. Product Portfolio
- 11.9.6. Business Performance
- 11.9.7. Key Strategic Moves and Developments
- 11.10. BAG Diagnostic GmbH
- 11.10.1. Company Overview
- 11.10.2. Key Executives
- 11.10.3. Company Snapshot
- 11.10.4. Operating Business Segments
- 11.10.5. Product Portfolio
- 11.10.6. Business Performance
- 11.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 2. HLA TYPING FOR TRANSPLANT MARKET FOR MOLECULAR ASSAY, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. HLA TYPING FOR TRANSPLANT MARKET FOR NON-MOLECULAR ASSAY, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 5. HLA TYPING FOR TRANSPLANT MARKET FOR INSTRUMENTS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 6. HLA TYPING FOR TRANSPLANT MARKET FOR REAGENTS CONSUMABLES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. HLA TYPING FOR TRANSPLANT MARKET FOR SOFTWARE SERVICES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 9. HLA TYPING FOR TRANSPLANT MARKET FOR DIAGNOSTIC, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 10. HLA TYPING FOR TRANSPLANT MARKET FOR RESEARCH, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 12. HLA TYPING FOR TRANSPLANT MARKET FOR ORGAN TRANSPLANT, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 13. HLA TYPING FOR TRANSPLANT MARKET FOR TISSUE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 15. HLA TYPING FOR TRANSPLANT MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 16. HLA TYPING FOR TRANSPLANT MARKET FOR HOSPITAL TRANSPLANT CENTER, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 17. HLA TYPING FOR TRANSPLANT MARKET FOR OTHER, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 18. HLA TYPING FOR TRANSPLANT MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 19. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 20. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 21. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 22. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 23. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 24. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 25. U.S. HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 26. U.S. HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 27. U.S. HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 28. U.S. HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 29. U.S. HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 30. CANADA HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 31. CANADA HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 32. CANADA HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 33. CANADA HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 34. CANADA HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 35. MEXICO HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 36. MEXICO HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 37. MEXICO HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 38. MEXICO HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 39. MEXICO HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 40. EUROPE HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 41. EUROPE HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 42. EUROPE HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 43. EUROPE HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 44. EUROPE HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 45. EUROPE HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 46. GERMANY HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 47. GERMANY HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 48. GERMANY HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 49. GERMANY HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 50. GERMANY HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 51. FRANCE HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 52. FRANCE HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 53. FRANCE HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 54. FRANCE HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 55. FRANCE HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 56. UK HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 57. UK HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 58. UK HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 59. UK HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 60. UK HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 61. ITALY HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 62. ITALY HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 63. ITALY HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 64. ITALY HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 65. ITALY HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 66. SPAIN HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 67. SPAIN HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 68. SPAIN HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 69. SPAIN HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 70. SPAIN HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 71. REST OF EUROPE HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 72. REST OF EUROPE HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 73. REST OF EUROPE HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 74. REST OF EUROPE HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 75. REST OF EUROPE HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 76. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 77. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 78. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 79. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 80. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 81. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 82. JAPAN HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 83. JAPAN HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 84. JAPAN HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 85. JAPAN HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 86. JAPAN HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 87. CHINA HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 88. CHINA HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 89. CHINA HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 90. CHINA HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 91. CHINA HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 92. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 93. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 94. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 95. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 96. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 97. INDIA HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 98. INDIA HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 99. INDIA HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 100. INDIA HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 101. INDIA HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 102. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 103. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 104. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 105. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 106. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 107. REST OF ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 108. REST OF ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 109. REST OF ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 110. REST OF ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 111. REST OF ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 112. LAMEA HLA TYPING FOR TRANSPLANT MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 113. LAMEA HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 114. LAMEA HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 115. LAMEA HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 116. LAMEA HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 117. LAMEA HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 118. BRAZIL HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 119. BRAZIL HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 120. BRAZIL HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 121. BRAZIL HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 122. BRAZIL HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 123. SAUDI ARABIA HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 124. SAUDI ARABIA HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 125. SAUDI ARABIA HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 126. SAUDI ARABIA HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 127. SAUDI ARABIA HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 128. SOUTH AFRICA HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 129. SOUTH AFRICA HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 130. SOUTH AFRICA HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 131. SOUTH AFRICA HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 132. SOUTH AFRICA HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 133. REST OF LAMEA HLA TYPING FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2024 - 2033 ($BILLION)
- TABLE 134. REST OF LAMEA HLA TYPING FOR TRANSPLANT MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
- TABLE 135. REST OF LAMEA HLA TYPING FOR TRANSPLANT MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
- TABLE 136. REST OF LAMEA HLA TYPING FOR TRANSPLANT MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 137. REST OF LAMEA HLA TYPING FOR TRANSPLANT MARKET, BY END USER, 2024 - 2033 ($BILLION)
- TABLE 138. LUMINEX CORPORATION: KEY EXECUTIVES
- TABLE 139. LUMINEX CORPORATION: COMPANY SNAPSHOT
- TABLE 140. LUMINEX CORPORATION: OPERATING SEGMENTS
- TABLE 141. LUMINEX CORPORATION: PRODUCT PORTFOLIO
- TABLE 142. LUMINEX CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 143. PACIFIC BIOSCIENCES OF CALIFORNIA, INC: KEY EXECUTIVES
- TABLE 144. PACIFIC BIOSCIENCES OF CALIFORNIA, INC: COMPANY SNAPSHOT
- TABLE 145. PACIFIC BIOSCIENCES OF CALIFORNIA, INC: OPERATING SEGMENTS
- TABLE 146. PACIFIC BIOSCIENCES OF CALIFORNIA, INC: PRODUCT PORTFOLIO
- TABLE 147. PACIFIC BIOSCIENCES OF CALIFORNIA, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 148. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 149. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 150. ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 151. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 152. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 153. BIO-RAD LABORATORIES: KEY EXECUTIVES
- TABLE 154. BIO-RAD LABORATORIES: COMPANY SNAPSHOT
- TABLE 155. BIO-RAD LABORATORIES: OPERATING SEGMENTS
- TABLE 156. BIO-RAD LABORATORIES: PRODUCT PORTFOLIO
- TABLE 157. BIO-RAD LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 158. BIOREFERENCE LABORATORIES: KEY EXECUTIVES
- TABLE 159. BIOREFERENCE LABORATORIES: COMPANY SNAPSHOT
- TABLE 160. BIOREFERENCE LABORATORIES: OPERATING SEGMENTS
- TABLE 161. BIOREFERENCE LABORATORIES: PRODUCT PORTFOLIO
- TABLE 162. BIOREFERENCE LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 163. QIAGEN N.V: KEY EXECUTIVES
- TABLE 164. QIAGEN N.V: COMPANY SNAPSHOT
- TABLE 165. QIAGEN N.V: OPERATING SEGMENTS
- TABLE 166. QIAGEN N.V: PRODUCT PORTFOLIO
- TABLE 167. QIAGEN N.V: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 168. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 169. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 170. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
- TABLE 171. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 172. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 173. ILLUMINA INC.: KEY EXECUTIVES
- TABLE 174. ILLUMINA INC.: COMPANY SNAPSHOT
- TABLE 175. ILLUMINA INC.: OPERATING SEGMENTS
- TABLE 176. ILLUMINA INC.: PRODUCT PORTFOLIO
- TABLE 177. ILLUMINA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 178. FUJIREBIO: KEY EXECUTIVES
- TABLE 179. FUJIREBIO: COMPANY SNAPSHOT
- TABLE 180. FUJIREBIO: OPERATING SEGMENTS
- TABLE 181. FUJIREBIO: PRODUCT PORTFOLIO
- TABLE 182. FUJIREBIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 183. BAG DIAGNOSTIC GMBH: KEY EXECUTIVES
- TABLE 184. BAG DIAGNOSTIC GMBH: COMPANY SNAPSHOT
- TABLE 185. BAG DIAGNOSTIC GMBH: OPERATING SEGMENTS
- TABLE 186. BAG DIAGNOSTIC GMBH: PRODUCT PORTFOLIO
- TABLE 187. BAG DIAGNOSTIC GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL HLA TYPING FOR TRANSPLANT MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF HLA TYPING FOR TRANSPLANT MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN HLA TYPING FOR TRANSPLANT MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHLA TYPING FOR TRANSPLANT MARKET
- FIGURE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION, BY TECHNOLOGY
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook